BUSM researchers part of multi-center study on cardiac amyloidosis

August 13, 2012

Researchers at Boston University School of Medicine (BUSM) have been part of a multicenter observational study called TRACS (Transthyretin Amyloidosis Cardiac Study) to help determine the health significance of a particular gene mutation which is commonly found in Black Americans.

The gene, transthyretin (TTR) and the mutation V122I, is seen in about four percent of African Americans or roughly 1.5 million people. The mutation is strongly associated with a condition called cardiac amyloidosis - a disorder where the abnormally mutated TTR protein deposits in the heart of affected individuals, causing the heart to not pump adequately and ultimately results in death. Cardiac amyloidosis due to this mutation is seen in older people, over the age of 60 years. Cardiac amyloidosis can be also be due to genetically normal TTR as well, which occurs for unclear reasons but is strongly associated with age and male gender.

The researchers enrolled 29 patients with TTR cardiac amyloidosis due to either the V122I mutation or those with genetically normal TTR, and observed them for roughly 16 months. They found that Black patients with the mutation only survived for a median of 26 months after diagnosis, and that certain measured parameters including by echocardiography, blood testing and fell during the study and were associated with survival. Quality of life determined by questionnaire also declined significantly. These findings currently appear online in the .

"This study is important because it establishes that carriers of V122I are at increased risk of death from cardiac once they reach an age where the disease is expressed (generally over the age of 60)," explained lead author Frederick L. Ruberg, MD, assistant professor of medicine and radiology at BUSM. According to Ruberg these findings provide an important foundation on which future studies using can be based. "If patients on the new drug live longer or decline more slowly than those in TRACS, that would suggest a beneficial effect to treatment," he added.

Explore further: Study leads to a promising first-in-class drug candidate

Related Stories

Study leads to a promising first-in-class drug candidate

July 21, 2009

Discoveries by Scripps Research Institute scientists have led to a promising new drug candidate--the first in its class--for patients with a genetic protein-misfolding disease. In results announced by the biopharmaceutical ...

Recommended for you

Amyloid-related heart failure now detectable with imaging test

August 24, 2016

A type of heart failure caused by a build-up of amyloid can be accurately diagnosed and prognosticated with an imaging technique, eliminating the need for a biopsy, according to a multicenter study led by researchers at Columbia ...

Biomarkers may help better predict who will have a stroke

August 24, 2016

People with high levels of four biomarkers in the blood may be more likely to develop a stroke than people with low levels of the biomarkers, according to a study published in the August 24, 2016, online issue of Neurology, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.